New combo therapy aims to shrink spleens and ease symptoms in myelofibrosis patients

NCT ID NCT06414681

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 25, 2026 · Updated 1 time

Summary

This early-stage trial tests a combination of two drugs, tagraxofusp and pacritinib, in about 20 adults with myelofibrosis (a type of bone marrow cancer) who have already tried standard JAK inhibitors or cannot take them. The main goals are to see if the combo can shrink an enlarged spleen by at least 35% and improve symptoms like fatigue and pain over 24 weeks. Researchers will also monitor side effects and track genetic changes in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS，MF are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The University of Kansas Cancer Center
RECRUITING

Fairway, Kansas, 66204, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MYELOFIBROSIS，MF